CompletedNCT00181870
Extended-release carbamazepine for mania in children ages 6–12 with bipolarity
About this title
Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder
Read the official source — NCT00181870Medication studyAges 6–12United States
Understand this study
Who was this study for?
Listed age limits: 6 years to 12 years.
- Listed locations
- CambridgeSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJuly 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 33
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT00181870
- Official title
Show the full official title
Open-Label Study of Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cambridge
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including carbamazepine ER (Equetro).
Who was this study for?
Listed age limits: 6 years to 12 years.
